Abivax SA American Depositary Shares (ABVX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Abivax SA American Depositary Shares stock (ABVX) is currently trading at $110.70. Abivax SA American Depositary Shares PS ratio (Price-to-Sales) is 1643.17. Analyst consensus price target for ABVX is $155.20. WallStSmart rates ABVX as Sell.
- ABVX PE ratio analysis and historical PE chart
- ABVX PS ratio (Price-to-Sales) history and trend
- ABVX intrinsic value — DCF, Graham Number, EPV models
- ABVX stock price prediction 2025 2026 2027 2028 2029 2030
- ABVX fair value vs current price
- ABVX insider transactions and insider buying
- Is ABVX undervalued or overvalued?
- Abivax SA American Depositary Shares financial analysis — revenue, earnings, cash flow
- ABVX Piotroski F-Score and Altman Z-Score
- ABVX analyst price target and Smart Rating
Abivax SA American Depositary Shares
📊 No data available
Try selecting a different time range
Smart Analysis
Abivax SA American Depositary Shares (ABVX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Abivax SA American Depositary Shares (ABVX) Key Strengths (2)
84.34% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Abivax SA American Depositary Shares (ABVX) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -52.70%, a shrinking business
Very expensive at 1643.2x annual revenue
Very expensive at 16.3x book value
Supporting Valuation Data
Abivax SA American Depositary Shares (ABVX) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 8.5/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (1643.17), Price/Book (16.28) suggest expensive pricing. Growth concerns include Revenue Growth at -52.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -106.40%, Operating Margin at -12631.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -106.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -52.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABVX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABVX's Price-to-Sales ratio of 1643.17x trades 177% above its historical average of 592.26x (83th percentile), historically expensive. The current valuation is 10% below its historical high of 1827.56x set in Mar 2026, and 3717% above its historical low of 43.05x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~46.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Abivax SA American Depositary Shares (ABVX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Abivax SA American Depositary Shares operates as a stable business with moderate growth and solid fundamentals. Revenue reached 5M with 53% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 1043% of revenue (55M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 53% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -71M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Abivax SA American Depositary Shares.
Bottom Line
Abivax SA American Depositary Shares offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:26:14 AM
About Abivax SA American Depositary Shares(ABVX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis and other indications. The company’s innovative approach integrates antibody-mediated therapies with proprietary compounds, targeting significant unmet medical needs in the healthcare market. With a robust pipeline and a dedicated scientific team, Abivax stands as an intriguing investment opportunity for institutional investors seeking to engage in the burgeoning immunotherapy sector.